Eris Lifesciences, Natco Pharma Partner to Commercialize Semaglutide in India

• Eris Lifesciences announced a partnership with Natco Pharma for the commercialization of semaglutide in India.
• Semaglutide is a GLP-1 receptor agonist used for Type 2 diabetes and chronic weight management.
• The collaboration leverages Eris's commercial and diabetes franchise strength and Natco's manufacturing and regulatory expertise.
• Eris Lifesciences Chairman and MD Amit Bakshi highlighted semaglutide as a significant therapeutic advance in metabolic care.
• The partnership aims to drive rapid adoption and enhance patient access to semaglutide in India.